Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Taiwan

June 6, 2012 Kowa Company, Ltd. Mitsubishi Tanabe Pharma Corporation Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Taiwan Kowa Company, Ltd. (Nagoya, President & CE O: Yoshihiro Miwa, hereinafter “Kowa”) and Mitsubishi Tanabe Pharma Corporation (Osaka, President: Michihiro Tsuchiya, hereinafter “Mitsubishi Tanabe Pharma”) announced today that a consolidated subsidiary of Mitsubishi Tanabe Pharma, Tai Tien Pharmaceuticals Co., Ltd. (Taipei, Taiwan), started marketing pitavastatin calcium (generic name, brand name in Japan: Livalo Tablets), a hypercholesterolemia treatment agent, in Taiwan on June 1, 2012, accord ing to the agreements on exclusive development and commercialization licenses for the drug between Kowa and Tai Tien Pharmaceuticals Co., Ltd. Pitavastatin, whose raw material is created a nd manufactured by Nissan Chemical Industries, Ltd., is commercialized (development, manufact ure, marketing and alliance) globally and exclusively by Kowa. As a new HMG-CoA re ductase inhibitor that exhibits strong LDL cholesterol lowering action. Pitavastatin is positioned as a strong statin, and due to many findings, apart from that excellent effect of dy slipidemia improvement, other characteristics such as safety in long-term use, decreases in the occurrence of drug-drug interactions and usefulness when patients have diabetes compli cation have also been confirmed. Kowa obtained manufacturing approval in Japan in July, 2003 and sales of the drug started in September of the same year. Sales of Livalo Tablets in 2010 in Japan reached ¥45 billion. Kowa is proactively promoting the overseas development and commercialization of drugs, aiming at the global expansion of its pharmaceuti cal business centered on pitavastatin. So far, Kowa has commenced sales of the drug in many countries including the U.S. and China through other business partners, and commenced sales in Spain, as the first launch in Europe, in May 2011, and in Mexico, as the first launch in the Central & South America, in February of this year. Pitavastatin is marketed in 11 overseas countries including Taiwan. Kowa will promote the global expansion of pitavastatin covering 5 continents within this year. Meanwhile, Mitsubishi Tanabe Pharma is curre ntly working on the promotion of overseas business expansion. In the U.S. and Europe, M itsubishi Tanabe Pharma is conducting in-house promotion such as premarketing and establishing sales system for kidney disease treatment, while in Asian countries; it works to rapidly launch new products and to strengthen operating basis through its subsidiaries in each country . Mitsubishi Tanabe Pharma expects early penetration of pitavastatin in Taiwanese ma rket and maximization of the sales through the excellent marketing capabilities of Tai Tien Phar maceuticals Co., Ltd. and the strong synergies with their good performance, experience of existing drugs in the cardiovascular area. Through this alliance, the companies will continue to work for maximization of the pitavastatin business as well as strengthening their business expans ions in Asia, a promising market in the world. [Reference] Pitavastatin global development Country or region name Status Launch (schedule) Marketing partner Japan Launched September 2003 Kowa Pharmaceutical Co. Ltd. Daiichi Sankyo Company, Limited Korea Launched July 2005 Choongwae Pharma Corporation Thailand Launched January 2008 Biopharm Chemical Co., Ltd. China Launched July 2009 *1 USA Launched June 2010 *2 Spain Launched May 2011 Recordati, Esteve Portugal Launched June 2011 Recordati, Delta Europe *3 2012 KPE, Recordati Lebanon Launched March 2011 Algorithm Middle East Preparing the application 2013 Algorithm Mexico Launched February 2012 Eli Lilly & Co. Indonesia Launched May 2012 P.T. Tanabe Indonesia Taiwan Launched June 2012 Tai Tien Pharmaceuticals Co., Ltd. Central & South America Application filed 2012 Eli Lilly & Co. Australia Approved 2012 Abbott *1 In China, Kowa is advancing the provision of information to medical institutions and doctors on the appropriate use of pitavastatin a nd conducting information gathering activities through Kowa (Shanghai) Phar ma Consulting Co., Ltd., a w holly-owned subsidiary of Kowa. *2 In the United States, Kowa Pharmaceuticals America, Inc. (Alabama, USA), a wholly-owned subsidiary of Kowa, sells and markets pitavast atin with a co-promotion partner, Eli Lilly (Indiana, USA). *3 Development in Europe Approved Ireland, U.K., Netherlands, Sweden, Norway, Finland, France, Belgium, Germany, Greece, Cyprus, Austria, Poland Application filed Italy Media inquiry Kowa Company, Ltd. Public Relations Department 2 TEL：+81-3-3279-7392 Mitsubishi Tanabe Pharma Corporation Corporate Communications Department TEL：+81-6-6205-5211

The release as fetched from its publisher. tanabe-pharma.com ↗